Elanco Partners with Medgene to Launch Avian Influenza Vaccine for Dairy Cattle

Elanco Animal Health Incorporated, a global leader in animal health, announced its partnership with South Dakota-based Medgene to commercialize a highly pathogenic avian influenza (HPAI) vaccine for dairy cattle. This strategic agreement aims to combat the cross-species transmission of the virus, which has affected nearly 1,000 dairy herds across the U.S. since March 2024.

While interventions in the poultry industry have struggled against the current outbreak entering its fourth year, the introduction of a cattle vaccine is seen as crucial for reducing virus spread between birds and cattle. The vaccine has met all requirements of the U.S. Department of Agriculture's platform technology guidelines and is in the final review stages for conditional license approval.

Jeff Simmons, President and CEO of Elanco Animal Health, emphasized the urgency of introducing new solutions to control disease spread, highlighting how avian influenza has impacted egg prices and milk production in affected areas. He stated, "Elanco is pleased to partner with Medgene to bring customers options to fight this devastating disease."

Medgene's CEO, Mark Luecke, expressed excitement over the partnership, noting the critical importance of the H5N1 vaccine for dairy cattle. With USDA approval of their vaccine platform technology, Medgene is prepared to support the U.S. dairy herd with existing vaccine manufacturing supply.

ABOUT ELANCO

Elanco Animal Health Incorporated is dedicated to innovating and delivering products to prevent and treat diseases in farm animals and pets. With 70 years of animal health heritage, Elanco strives to improve animal health and impact communities globally.